270 East Grand Avenue
South San Francisco
About Portola Pharmaceuticals
We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.
Founding date: September 23, 2003
CEO: Scott Garland (effective 10/8/18)
CFO: Mardi Dier
Executive VP, R&D: John Curnutte MD PhD
Executive VP, Chief Human Resources Officer: Ernie Meyer
Executive VP, General Counsel: John Moriarty
Senior VP, Technical Operations: Glenn Brame
Senior VP, Chief Medical Officer: John H. (Jack) Lawrence MD
215 articles with Portola Pharmaceuticals
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya™ (andexanet alfa)
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authorization application (MAA) for Ondexxya™ (andexanet alfa).
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately.
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban – – Full Commercial Launch to Begin January 2019
With the holidays upon us, along with the end of 2018 and the beginning of 2019, the FDA squeezed some target action dates into the last weeks and beginning of the new year. As it turned out, these appear to be a mixed bag of extensions, resubmissions and supplemental applications, some of which ...
Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
Portola Pharmaceuticals’ chief executive officer, William Lis, plans to retire as both chief executive and board member.
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
The U.S. Food and Drug Administration (FDA) approved Portola Pharmaceuticals’ Andexxa, an antidote for blood thinners rivaroxaban and apixaban.
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
Shares of Portola Pharmaceuticals are falling after the company announced a delay of several months for possible regulatory approval of its Factor Xa-inhibitor antidote, AndexXa.
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
The data will be presented on Monday, March 12, 2018 at 11:30 a.m. ET.
1/15/2018Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
The FDA communicated that the action date will move from February 3, 2018 to May 4, 2018.
The FDA continues to hand out some early Christmas presents to pharma companies.
Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban
The CHMP has provided the Day 195 List of Outstanding Issues (LoOI) to the company with a request for responses during the next available submission window of January 23, 2018.
Portola granted to Mr. Lawrence an award in the form of 5,000 restricted stock units.